Objective: The aim of the present study was to investigate the use of random copeptin concentrations as possible biomarkers for the differential diagnosis of nocturnal polyuria (NP).
| INTRODUCTION
Nocturia is defined as waking once or more during the night with the need to void. 1 Although the pathophysiology of nocturia can be multifactorial and complex, the core of the problem is nocturnal urine volume exceeding nocturnal bladder capacity. The causes can be categorized into 4 groups: nocturnal polyuria (NP), global polyuria, reduced bladder capacity (RBC), or a combination of these 3. 2 In the present study we focus primarily on NP.
Nocturnal polyuria is defined as an increase in overnight urine production, with 24-hour urine production within normal limits. 3 The
International Continence Society (ICS) defines NP as nocturnal urine production (NUP) exceeding 33% of total urine output. 1 Several other definitions exist, but there is no true consensus as to which definition is the most clinically relevant. 4 Studies have identified a disruption in the circadian rhythm of antidiuretic hormone (ADH) as one of the primary causes of NP. [5] [6] [7] [8] [9] In children and young healthy males, there is a nocturnal increase in ADH levels, which decreases water diuresis and thus urine production.
This circadian rhythm becomes less pronounced with age, but the impairment is also found in younger adults with NP and children with nocturnal enuresis. [5] [6] [7] [8] [9] Other studies have described an increase in either water or solute diuresis, or their combination, as the underlying pathophysiologic mechanism of NP. 10 Treatment of NP consists of substitution of low nocturnal ADH with desmopressin. Therefore, it is possible that ADH could be an interesting marker for the diagnosis of NP, but analysis of ADH is unreliable due to its small molecular size and short half-life. In contrast with ADH, copeptin, the C-terminal part of pre-pro-vasopressin, is much more stable and can be easily measured by ELISA. Copeptin is secreted in a 1 : 1 ratio with ADH, and can be used as a surrogate for ADH.
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The aim of the present study was to explore whether random copeptin concentrations can be used to identify patients with NP.
2 | METHODS
| Patient selection and data collection
The present study was a retrospective analysis of an observational study performed at Ghent University Hospital between October 2011
and May 2013. and (2) NUP >10 mL/kg bodyweight (NUP10). Global polyuria was diagnosed when total urine volume exceeded 40 mL/kg/24 h.
Reduced bladder capacity (RBC) was diagnosed in case of a mean functional bladder capacity <250 mL. All subjects were then redistributed into 3 groups: those with NP, those with global polyuria, and a control group. Subjects with only RBC were seen as the control group, because we reasoned they would not have ADH deficiency, in contrast with the other 2 groups. To make a distinction between an increase in water or solute diuresis, cut-off values were used as proposed by Goessaert et al. 12 Osmolality and plasma sodium and creatinine concentrations were also determined for all subjects and used to calculate the renal clearance of sodium and creatinine as follows:
where Usubst is the urinary concentration of the substance, Uflow is urinary flow and Psubst is the concentration of the substance in the plasma. Because the present study was an observational study, blood sampling occurred during patient consultations in the outpatient clinic, and the timing of collection was random, reflecting the real-life situation. Plasma samples were obtained by centrifugation of blood samples at 2400g for 10 minutes at 4 C within 1 hour of collection and stored in aliquots at -20 C or -80 C for later analysis. Plasma copeptin concentrations (pM) were determined using a sandwich immunoassay in September 2015 at Aarhus University Hospital. The lower limit of detection of the assay was 0.9 pM and the functional sensitivity of the assay (interassay coefficient of variation <20%) was <2 pM.
| Statistical analysis
Statistical analyses were performed using SPSS v.22 for Windows.
The Shapiro-Wilk W-test was used to determine whether variables were normally distributed. The median, interquartile range (IQR), and frequency were recorded as descriptive statistical parameters.
Differences between 2 non-parametric variables were assessed using the Mann-Whitney U-test, whereas differences between more than 2 variables were evaluated using the Kruskal-Wallis test. Correlation coefficients were calculated using non-parametric Spearman correlation. P < .05 was considered statistically significant.
This study was approved by the Ghent University Hospital review board (EC 2011/565). The Declaration of Helsinki was followed and the study was conducted in accordance with the legal regulations in Belgium. Written informed consent was obtained from all individuals included in the study.
3 | RESULTS
| General population
In all, 111 subjects (median age 61 years; IQR 49-67 years) were included in the study, 48% of whom were female. Seventy-six participants (68%) had at least 1 episode of nocturia per night. Median (IQR)
voiding scores on the ICIQ-F-LUTS and ICIQ-M-LUTS were 1 (0-3) and 7 (1.5-9), respectively, whereas median (IQR) incontinence scores were 2 (0-4) and 3 (1-5) respectively. The median filling score on the ICIQ-F-LUTS was 4 (2-6.5). Figure 1 ). Copeptin concentrations did not differ according to the number of nocturnal voids (P = .138). There was a significant positive correlation between copeptin and both urine and plasma osmolality (r=0.43 and 0.56 respectively; both P < .001), as well as a negative correlation between copeptin and both the 24-hour diuresis rate (P = .002) and free water clearance (r=−0.38 and −0.29 respectively both; P < .001). There was no correlation between copeptin concentrations and sodium clearance (P = .233; Figure 2 ). There was no significant difference in copeptin concentrations between the NP and control groups (P = .972). Repeating the analysis using Figure 3 ).
| Nocturnal polyuria
several other NP definitions resulted in similar results as obtained using the NPi33 definition, except when the NUP10 definition was used.
| DISCUSSION
Nocturnal polyuria is one of the main causes of nocturia. An impairment of the circadian rhythm of ADH has been identified as an important pathophysiologic mechanism of NP, which leads to an increase in nocturnal water diuresis and thus increased NUP.
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From a pathophysiologic point of view, ADH is a promising parameter, but measurement of ADH is difficult. Copeptin is a byproduct of the ADH precursor pre-pro-vasopressin and is released in an equimolar ratio proportional to ADH. Copeptin peptide is more stable and easier to measure than ADH, which makes it a more accessible potential biomarker. 11 In the present study, the copeptin concentration was correlated with urine and plasma osmolality, as well as FWC, but not solute clearance, which confirms its role as a surrogate for ADH.
Most research on copeptin has focused on its potential role as a biomarker in severe diseases, such as sepsis, heart failure, and myocardial infarction. Vasopressin is released when the body is in severe stress in an attempt to restore vascular tone and filling status. 13 In several studies, copeptin and vasopressin have been compared with Btype natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), a peptide that increases natriuresis, diuresis, and vasodilatation under physiological conditions. 14-16 Measurements of BNP and NT-proBNP are used as prognostic markers in acute and chronic heart failure, whereby increased values are correlated with worse outcome. [14] [15] [16] Copeptin concentrations are also increased in the critically ill, with higher values in patients with adverse outcomes such as death, compared with survivors. [14] [15] [16] Therefore, these peptides seem to be closely related as a prognostic markers, 14-16 even though they have opposite functions under physiological conditions.
The aim of the present study was to investigate the relationship between copeptin and NP in an adult population, in which we expected to see lower values in those subjects with an impaired vasopressin circadian rhythm. We were not able to confirm lower copeptin concentrations in NP compared with control subjects, but there was a significant difference between these 2 groups and patients with global polyuria, although this varied depending on the definition of NP used.
When the NUP10 definition was used, copeptin concentrations were comparable between subjects with NP and global polyuria. This may be explained by the fact that both definitions use the urine volume/ bodyweight ratio. Patients who met the criteria for global polyuria did have low copeptin concentrations in general; this could be due to primary polydipsia or central diabetes insipidus. A fluid deprivation test would be able to differentiate between the two. 17 Nalbantoğlu et al.
demonstrated a role for copeptin in monosymptomatic nocturnal enuresis in children, in whom lower values were associated with more severe symptoms. 18 The adult population in the present study is far more diverse, because some patients with NP did not have nighttime symptoms due to a larger bladder capacity, and others also exhibited daytime symptoms due to an RBC. Because the original focus of the study was to investigate circadian rhythms of diuresis and natriuresis in the RFP, it was not set up as a randomized controlled trial, but rather as a prospective observational study. Because of the retrospective design and small sample size in the present study, we were unable to correct for differences in age, ICIQ-M-LUTS or ICIQ-F-LUTS scores, Unless indicated otherwise, data are presented as the median [interquartile range]. The definitions of NP used were a nocturnal polyuria index, calculated as nocturnal urine production (NUP) as a percentage of 24-hour urine production, >33% (NPi33) and NUP >10 mL/kg bodyweight (NUP10). Copeptin (pM) FIGURE 3 Copeptin concentrations according to the underlying pathophysiologic mechanism. Two definitions of nocturnal polyuria were used: (1) a nocturnal polyuria index, calculated as nocturnal urine production (NUP) as a percentage of 24-hour urine production, >33% (NPi33); and (2) NUP >10 mL/kg bodyweight (NUP10 The present study is the first exploratory study assessing the relationship between copeptin and nocturia. We could not confirm our hypothesis that patients with NP have lower copeptin concentrations.
There are no other studies with which to compare our results, nor cut-off values for low copeptin concentrations in adults. Further testing is needed to determine the best conditions (fasting, fluid restriction etc.) and the best time (morning, evening) to determine copeptin concentrations in a nocturia population, and to assess the association between copeptin concentrations and FVC and RFP. In addition, prospective case-control studies comparing copeptin concentrations between desmopressin responders and non-responders may show that copeptin can be used to guide treatment choices in patients with nocturia or NP.
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